Matt Britz is the Chief Executive Officer of Saros Therapeutics. Matt recently served as CEO of AffyImmune Therapeutics, where he played a pivotal role in advancing novel CAR T cell therapies for solid tumors. During his tenure, he helped guide the company’s lead program through early clinical development and established a focused pipeline targeting high unmet medical needs. Prior to AffyImmune, Matt held senior executive positions at Minerva Biotechnologies, Equinox Group, Health Advances, Pfizer, Merck, and Envoy Therapeutics, where he was instrumental in the company’s acquisition by Takeda.

Matt Britz holds an MBA from Washington University in St. Louis and Bachelor’s degrees in Chemical Engineering and Biology from the Massachusetts Institute of Technology (MIT). His experience spans the full spectrum of drug development, from discovery through commercialization, and includes leadership in business development, manufacturing, clinical operations, regulatory affairs, and program management.